Skip to main content
. 2015 Jul 25;19(2):pyv082. doi: 10.1093/ijnp/pyv082

Table 1.

Demographic Information and Study Design of Included Placebo-Controlled Trials

Study names Study Length
(weeks)		 Diagnostic Criteria Age (range, mean ± SD) Sex (% female) Treatment Group (n) Cognitive Testing Effect (+/-/neutral), statistically NS
McIntyre et al., 2014 8 -DSM IV
-TR
-MDD
-MADRS ≥ 26
-Current MDE ≥ 3 months		 18–65
45.4±12.2
68.7%
45.6±12.1
65.8%		 Vortioxetine 10mg (192)
vs
Placebo (194)		 Composite z-score [DSST/ RAVLT(acq)/RAVLT (delay)]
DSST(correct Symbols)
RAVLT(acquisition)
RAVLT(delayed recall)
TMT-A
TMT-B
SRT
CRT
Stroop(congruent)
Stroop(incongruent)
PDQ(total score)		 +ve p < 0.001
+ve p < 0.001
+ve p = 0.029
+ve p = 0.003
+ve p = 0.006
+ve p = 0.006
+ve p < 0.001
+ve p < 0.001
+ve p = 0.002
+ve p = 0.001
+ve p < 0.001
46.1±11.8
64.3%
45.6±12.1
65.8%		 Vortioxetine 20mg (204)
vs
Placebo (194)		 Composite z-score [DSST/ RAVLT(acq)/RAVLT (delay)]
DSST(correct symbols)
RAVLT(acquisition)
RAVLT(delayed recall)
TMT-A
TMT-B
SRT
CRT
Stroop(congruent)
Stroop(incongruent)
PDQ(total score)		 +ve p < 0.001
+ve p < 0.001
+ve p = 0.199
+ve p = 0.007
+ve p = 0.005
+ve p < 0.001
+ve p = 0.016
+ve p = 0.355
+ve p < 0.001
+ve p = 0.001
+ve p < 0.001
Katona et al., 2012 8 -DSM IV
-TR
-MDD
-MADRS ≥ 26
-Current MDE ≥ 4wks (at least 2nd episode)		 65+
70.5±4.8
68.6%
70.3±4.4
62.1%		 Vortioxetine 5mg (156)
vs
Placebo (145)		 DSST(correct symbols)
RAVLT(acquisition)
RAVLT(delayed recall)		 +ve p < 0.05
+ve p < 0.05
+ve p < 0.05
70.9±5.5
66.2%
70.3±4.4
62.1%		 Duloxetine 60mg (151)
vs
Placebo (145)		 DSST(correct symbols)
RAVLT(acquisition)
RAVLT(delayed recall)		 Neutral NS
+ve p < 0.01
+ve p < 0.01
Mahableshwarkar et al., 2015 8 -DSM IV
-TR
-MDD
-MADRS ≥ 26
-Recurrent MDD with current MDE		 18–65
44.2±12.2168.2%
45.0±12.0761.3%		 Vortioxetine10-20mg
(175)
vs
Placebo (167)		 DSST(correct symbols)
PDQ
TMT-A
TMT-B
Stroop(congruent)
Stroop(incongruent)		 +ve p = 0.019
+ve p = 0.001
+ve p = 0.446
+ve p < 0.001
+ve p = 0.482
+ve p = 0.980
45.7±11.4665.7%
45.0±12.0761.3%		 Duloxetine 60mg
(187)
vs
Placebo (167)		 DSST(correct symbols)
PDQ
TMT-A
TMT-B
Stroop(congruent)
Stroop(incongruent)		 +ve p = 0.099
+ve p < 0.001
+ve p = 0.303
+ve p = 0.053
+ve p = 0.904
+ve p = 0.422
Raskin et al., 2007 8 -DSM IV
-MDD
-HAMD(17) ≥18
-Recurrent MDD with current MDE		 65+
72.6±5.7
60.4%
73.3±5.7
57.7%		 Duloxetine 60mg
(196)
vs
Placebo (99)		 Verbal learning and recall test
(learning trials)
(delayed recall)
DSST(correct symbols)
Two-digit cancellation test
Letter-number sequencing test		 +ve p = 0.03
+ve p = 0.02
Neutral NS
Neutral NS
Neutral NS
Robinson et al., 2014 24 -DSM IV
-TR
-MDD
-MADRS ≥ 20
-Current MDE		 65+
73.01±6.2666.2
73.1±5.64
58.9%		 Duloxetine
60 or 120mg
(180)
Placebo
(87)		 Verbal learning and recall test
(learning trials)
(delayed recall)
DSST(correct symbols)
Two-digit cancellation test
TMT-B		 Neutral NS
Neutral NS
Neutral NS
Neutral NS
Neutral NS
Culang et al., 2009 8 -DSM IV-MDD
-HRSD(24) ≥ 20
-Curent MDE		 75+
79.82±3.9754%
79.33±4.6962%		 Citalopram
20mg (40mg if HRSD > 10 after 4 wks)
(84)
Placebo (90)		 DSST
Stroop
CRT
JOLO
Buschke SRT		 Neutral NS
Neutral NS
Neutral NS
Neutral NS
Neutral NS
Ferguson et al., 2003 8 -DSM IV
-MDD
-HAM-D(17) ≥ 20		 18–65
Not available		 Paroxetine
20–40mg (23)
vs
Placebo (26)		 Continuity of Attention
Combined speed		 Neutral NS
Neutral NS
Georgotas et al., 1989 7 -MDD Diagnosisa
-HRSD(21) ≥ 16		 55+
64.7±6.8
55.1%
(age for all groups totaled)		 Nortriptyline
(32)
vs
Phenelzine
(28)
vs
Placebo
(18)
(Dosing not specified)		 Paragraph recall
Paragraph recall delay
Paired associated recall
WAIS Vocobularly
DSST
Mental Status Questionaire
Name-Face Test
Peterson and Peterson
Finger tapping
Buschke Retrieval Task		 Neutral NS
Neutral NS
Neutral NS
Neutral NS
Neutral NS
Neutral NS
Neutral NS
Neutral NS
Neutral NS
Neutral NS
Hoffman et al., 2008 16 -DSM IV- MDD
-BDI-II ≥ 12
-HAM-D(29)		 40+
51.8 ± 7.7
75.5%
51.2 ± 7.8
77.5%		 Sertraline
50–200mg
(49)
Placebo
(49)		 Logical memory
Verbal pairs, easy
Verbal pairs, hard
Digits forward
Digits Backwards
Animal naming
COWAT
Stroop
Ruff total
DSST
TMT-B		 Neutral NS
Neutral NS
Neutral NS
Neutral NS
Neutral NS
Neutral NS
Neutral NS
Neutral NS
Neutral NS
Neutral NS
Neutral NS

aMDD diagnosed by research diagnostic criteria

BDI-II, Beck Depression Inventory-II; Buschke SRT, Buschke Selective Reminding Test; COWAT, Wechsler Adult Intelligence Scale, Controlled Oral Word Association Test; CRT, Cognitive Reflection Test; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders; DSST, Digit Symbol Sign Test; HAM-D, Hamilton Rating Scale For Depression; HRSD, Hamilton Rating Scale For Depression; JOLO, Judgment of Line Orientation; MADRS, Montgomery-Asberg Depression Rating Scale; MDD, Major Depressive Disorder; MDE, Major Depressive Episode; NS, non-significant; PDQ, Perceived Deficit Questionnaire; RAVLT, Rey Auditory Verbal Learning Test; SD, standard deviation SRT, Simple Reaction Time; TMT-A or -B, Trails Making Test; TR, text revision; WAIS, Wechsler Adult Intelligence Scale.